0.3137
0.60%
-0.0019
Pre-market:
.3137
Kazia Therapeutics Limited ADR stock is currently priced at $0.3137, with a 24-hour trading volume of 295.10K.
It has seen a -0.60% decreased in the last 24 hours and a +12.44% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.301 pivot point. If it approaches the $0.3346 resistance level, significant changes may occur.
Kazia Therapeutics Limited ADR Stock (KZIA) Financials Data
Kazia Therapeutics Limited ADR (KZIA) Net Income 2023
KZIA net income (TTM) was -$13.52 million for the quarter ending June 30, 2023.
Kazia Therapeutics Limited ADR (KZIA) Cash Flow 2023
KZIA recorded a free cash flow (TTM) of -$10.03 million for the quarter ending June 30, 2023.
Kazia Therapeutics Limited ADR (KZIA) Earnings per Share 2023
KZIA earnings per share (TTM) was -$0.74 for the quarter ending June 30, 2023.
About Kazia Therapeutics Limited ADR
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.
Cap:
|
Volume (24h):